EZH2-driven immune evasion defines high-risk pediatric AML with t(16;21) FUS::ERG gene fusion.
Nathaniel J ButeynConnor G BurkeVincent J SartoriEve Deering-GardnerZachary J DeBruineDahlya KamarudinDarrell P ChandlerAlexander C MonovichMonika W PerezJoanna S YiRhonda E RiesTodd A AlonzoRussell J H RyanSoheil MeshinchiTimothy J TrichePublished in: bioRxiv : the preprint server for biology (2024)
pAML patients have dismal outcomes. Here we show a ubiquitous immune-evasive phenotype, defined by elevated EZH2 levels and loss of MHC class I and II receptors, is present in these patients at diagnosis. Treatment with the EZH2 inhibitor Tazemetostat successfully reverses the phenotype in a patient-derived cell line model.
Keyphrases
- end stage renal disease
- newly diagnosed
- chronic kidney disease
- long non coding rna
- prognostic factors
- peritoneal dialysis
- type diabetes
- acute myeloid leukemia
- patient reported outcomes
- long noncoding rna
- genome wide
- copy number
- young adults
- smoking cessation
- combination therapy
- allogeneic hematopoietic stem cell transplantation